CN113754581A - 可用于治疗癌症和糖尿病的6-芳基-4-吗啉-1-基吡啶酮化合物 - Google Patents

可用于治疗癌症和糖尿病的6-芳基-4-吗啉-1-基吡啶酮化合物 Download PDF

Info

Publication number
CN113754581A
CN113754581A CN202111121825.5A CN202111121825A CN113754581A CN 113754581 A CN113754581 A CN 113754581A CN 202111121825 A CN202111121825 A CN 202111121825A CN 113754581 A CN113754581 A CN 113754581A
Authority
CN
China
Prior art keywords
methyl
phenyl
pyridin
cancer
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111121825.5A
Other languages
English (en)
Chinese (zh)
Inventor
杰西卡·马丁松
马丁·安德松
约翰·林德斯特罗姆
里卡德·福斯布罗姆
弗雷德里克·拉姆
托拜厄斯·因曼
詹妮·维克兰德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sprint Bioscience AB
Original Assignee
Sprint Bioscience AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sprint Bioscience AB filed Critical Sprint Bioscience AB
Publication of CN113754581A publication Critical patent/CN113754581A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202111121825.5A 2016-02-19 2017-02-17 可用于治疗癌症和糖尿病的6-芳基-4-吗啉-1-基吡啶酮化合物 Pending CN113754581A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16156530.4 2016-02-19
EP16156530 2016-02-19
CN201780013738.3A CN108698996B (zh) 2016-02-19 2017-02-17 可用于治疗癌症和糖尿病的6-芳基-4-吗啉-1-基吡啶酮化合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780013738.3A Division CN108698996B (zh) 2016-02-19 2017-02-17 可用于治疗癌症和糖尿病的6-芳基-4-吗啉-1-基吡啶酮化合物

Publications (1)

Publication Number Publication Date
CN113754581A true CN113754581A (zh) 2021-12-07

Family

ID=55404645

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202111121825.5A Pending CN113754581A (zh) 2016-02-19 2017-02-17 可用于治疗癌症和糖尿病的6-芳基-4-吗啉-1-基吡啶酮化合物
CN202111123598.XA Pending CN113845472A (zh) 2016-02-19 2017-02-17 可用于治疗癌症和糖尿病的6-芳基-4-吗啉-1-基吡啶酮化合物
CN201780013738.3A Active CN108698996B (zh) 2016-02-19 2017-02-17 可用于治疗癌症和糖尿病的6-芳基-4-吗啉-1-基吡啶酮化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202111123598.XA Pending CN113845472A (zh) 2016-02-19 2017-02-17 可用于治疗癌症和糖尿病的6-芳基-4-吗啉-1-基吡啶酮化合物
CN201780013738.3A Active CN108698996B (zh) 2016-02-19 2017-02-17 可用于治疗癌症和糖尿病的6-芳基-4-吗啉-1-基吡啶酮化合物

Country Status (19)

Country Link
US (3) US11077113B2 (enExample)
EP (1) EP3416945B1 (enExample)
JP (3) JP6997462B2 (enExample)
CN (3) CN113754581A (enExample)
AU (3) AU2017219846B2 (enExample)
CY (1) CY1123285T1 (enExample)
DK (1) DK3416945T3 (enExample)
ES (1) ES2816376T3 (enExample)
HR (1) HRP20201400T1 (enExample)
HU (1) HUE050863T2 (enExample)
LT (1) LT3416945T (enExample)
PL (1) PL3416945T3 (enExample)
PT (1) PT3416945T (enExample)
RS (1) RS60898B1 (enExample)
RU (1) RU2754664C2 (enExample)
SI (1) SI3416945T1 (enExample)
SM (1) SMT202000523T1 (enExample)
TW (1) TWI721104B (enExample)
WO (1) WO2017140841A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3416945T3 (pl) * 2016-02-19 2020-12-28 Sprint Bioscience Ab Związki 6-arylo-4-(morfolin-4-ylo)-1h-pirydyn-2-onu przydatne w leczeniu nowotworu i cukrzycy
PT3416957T (pt) * 2016-02-19 2020-09-25 Sprint Bioscience Ab Compostos 6-heterociclil-4-morfolin-4-ilpiridin-2-ona úteis para o tratamento do cancro e da diabetes
HRP20220497T1 (hr) * 2017-08-23 2022-05-27 Sprint Bioscience Ab Spoj morfolinilpiridona
IL302356A (en) * 2017-08-23 2023-06-01 Sprint Bioscience Ab Pyridylpyridone compounds
PL3672948T3 (pl) * 2017-08-23 2022-12-05 Sprint Bioscience Ab Związki pirydynoamino-pirydonu i pirymidynoamino-pirydonu
IL302355A (en) 2017-08-23 2023-06-01 Sprint Bioscience Ab Azaindolylpyridone and diazaindolylpyridone compounds
WO2020008046A1 (en) 2018-07-06 2020-01-09 Sprint Bioscience Ab Biomarker
US12540115B2 (en) * 2019-08-21 2026-02-03 The Board Of Trustees Of The Leland Stanford Junior University Inhibitors of phospholipid synthesis and methods of use
JP2023550638A (ja) 2020-11-25 2023-12-04 デシフェラ・ファーマシューティカルズ，エルエルシー ウイルス感染症の処置に使用するための、ｖｓｐ３４阻害剤としてのモルホリノ誘導体
WO2022115549A1 (en) 2020-11-25 2022-06-02 Deciphera Pharmaceuticals, Llc Anti-viral activity of vps34 inhibitors
CN117083064A (zh) 2020-11-25 2023-11-17 德西费拉制药有限责任公司 作为vps34抑制剂用于治疗病毒感染的吡啶基吡啶酮衍生物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130289031A1 (en) * 2010-12-23 2013-10-31 Sanofi Pyrimidinone derivatives, preparation thereof and pharmaceutical use thereof
US20130338159A1 (en) * 2010-12-21 2013-12-19 Novartis Ag Bi-heteroaryl compounds as vps34 inhibitors
US20140275003A1 (en) * 2013-03-14 2014-09-18 Novartis Ag Biaryl amide compounds as kinase inhibitors
WO2014145512A2 (en) * 2013-03-15 2014-09-18 President And Fellows Of Harvard College Potent small molecule inhibitors of autophagy, and methods of use thereof
WO2015030057A1 (ja) * 2013-08-29 2015-03-05 富士フイルム株式会社 新規なモルホリン誘導体またはその塩
CN104603113A (zh) * 2012-06-22 2015-05-06 赛诺菲 包含经取代吗啉的新型2,3-二氢-1H-咪唑并{1,2-a}嘧啶-5-酮和1,2,3,4-四氢嘧啶并{1,2-a}嘧啶-6-酮衍生物、其制备及其制药用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2316831T3 (da) 2002-11-21 2013-06-10 Novartis Ag 2-(Morpholin-4-yl)pyrimidiner som phosphotidylinositol (PI)-3-kinaseinhibitorer samt deres anvendelse ved behandling af cancer
GB2465405A (en) * 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
PL2448940T3 (pl) 2009-07-02 2014-10-31 Sanofi Sa Pochodne 6,7,8,9-tetrahydro-pirymido{1,2-a} pirymidyn-4-onu, ich wytwarzanie i zastosowanie farmaceutyczne
GB201120317D0 (en) 2011-11-24 2012-01-04 Queen Mary & Westfield College Screening method
TN2016000270A1 (en) 2014-01-14 2017-10-06 Millennium Pharm Inc Heteroaryls and uses thereof.
WO2015108881A1 (en) 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
MA39822A (fr) 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
MA39823A (fr) 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
JP2017528486A (ja) * 2014-09-17 2017-09-28 ヴァーセオン コーポレイション セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物
PL3416945T3 (pl) * 2016-02-19 2020-12-28 Sprint Bioscience Ab Związki 6-arylo-4-(morfolin-4-ylo)-1h-pirydyn-2-onu przydatne w leczeniu nowotworu i cukrzycy

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130338159A1 (en) * 2010-12-21 2013-12-19 Novartis Ag Bi-heteroaryl compounds as vps34 inhibitors
US20130289031A1 (en) * 2010-12-23 2013-10-31 Sanofi Pyrimidinone derivatives, preparation thereof and pharmaceutical use thereof
CN104603113A (zh) * 2012-06-22 2015-05-06 赛诺菲 包含经取代吗啉的新型2,3-二氢-1H-咪唑并{1,2-a}嘧啶-5-酮和1,2,3,4-四氢嘧啶并{1,2-a}嘧啶-6-酮衍生物、其制备及其制药用途
US20140275003A1 (en) * 2013-03-14 2014-09-18 Novartis Ag Biaryl amide compounds as kinase inhibitors
WO2014145512A2 (en) * 2013-03-15 2014-09-18 President And Fellows Of Harvard College Potent small molecule inhibitors of autophagy, and methods of use thereof
WO2015030057A1 (ja) * 2013-08-29 2015-03-05 富士フイルム株式会社 新規なモルホリン誘導体またはその塩

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
来源于AURORA FINE CHEMICALS等提供的产品目录: "STN检索报告", 数据库REGISTRY（在线）, 24 February 2009 (2009-02-24), pages 1 - 5 *

Also Published As

Publication number Publication date
US11077113B2 (en) 2021-08-03
JP6997462B2 (ja) 2022-01-17
HUE050863T2 (hu) 2021-01-28
AU2021215234A1 (en) 2021-09-02
JP2024016225A (ja) 2024-02-06
SI3416945T1 (sl) 2020-11-30
CN108698996A (zh) 2018-10-23
US20220117974A1 (en) 2022-04-21
JP2022022368A (ja) 2022-02-03
JP7389504B2 (ja) 2023-11-30
PT3416945T (pt) 2020-09-11
RS60898B1 (sr) 2020-11-30
SMT202000523T1 (it) 2020-11-10
US20210128571A1 (en) 2021-05-06
CN108698996B (zh) 2021-10-01
AU2017219846B2 (en) 2021-05-13
AU2021215234B2 (en) 2023-10-26
HRP20201400T1 (hr) 2020-11-27
EP3416945A1 (en) 2018-12-26
RU2754664C2 (ru) 2021-09-06
US20240050439A1 (en) 2024-02-15
US11633403B2 (en) 2023-04-25
DK3416945T3 (da) 2020-09-21
TWI721104B (zh) 2021-03-11
WO2017140841A1 (en) 2017-08-24
CY1123285T1 (el) 2021-12-31
AU2017219846A1 (en) 2018-10-04
LT3416945T (lt) 2020-11-25
ES2816376T3 (es) 2021-04-05
PL3416945T3 (pl) 2020-12-28
CN113845472A (zh) 2021-12-28
TW201731841A (zh) 2017-09-16
CA3015045A1 (en) 2017-08-24
EP3416945B1 (en) 2020-07-01
JP2019505594A (ja) 2019-02-28
RU2018131775A3 (enExample) 2020-04-08
RU2018131775A (ru) 2020-03-20
AU2023248170A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
CN108698996B (zh) 可用于治疗癌症和糖尿病的6-芳基-4-吗啉-1-基吡啶酮化合物
CN108884067B (zh) 可用于治疗癌症和糖尿病的6-杂环基-4-吗啉-4-基吡啶-2-酮化合物
US11208423B2 (en) Pyridinamine-pyridone and pyrimidinamine- pyridone compounds
CN111094244B (zh) 吡啶基吡啶酮化合物
KR102731945B1 (ko) 아자인돌릴피리돈 및 디아자인돌릴피리돈 화합물
TWI803511B (zh) 嗎啉基吡啶酮化合物
CA3015045C (en) 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211207

WD01 Invention patent application deemed withdrawn after publication